This is an interlocutory ruling on a single executive's motion — not a final judgment against Sandoz. Monitor for trial developments and any settlement discussions among the remaining defendants. The statute of limitations briefing on two drugs may narrow the case further.
Price Chart
Executive Summary
The court largely denied former Sandoz executive Michael Perfetto's motion for summary judgment in a multi-state generic drug price-fixing conspiracy case, allowing claims on 7 drugs to proceed to trial. The ruling is a partial loss for Sandoz as a defendant in the broader litigation, but it is an interlocutory ruling on an individual executive's motion — not a final judgment against the company. No damages were awarded, and no injunction was issued against Sandoz.
Court Ruling Details
Key Facts
- Court denied summary judgment for Perfetto on claims involving Clindamycin, Econazole, Fluocinonide .1% cream, Fluocinonide gel, Fluocinonide solution (Taro agreement), Metronidazole cream/lotion, and Terconazole.
- Court granted summary judgment for Perfetto on claims involving Acetazolamide, Ammonium Lactate, Carbamazepine ER, Desonide, Halobetasol, Hydrocortisone valerate, Metronidazole 1% gel, Nystatin ointment, and Phenytoin.
- Court granted summary judgment on the States' claim for injunctive relief against Perfetto (he retired in 2017).
- Court deferred ruling on Clotrimazole 1% cream and Triamcinolone acetonide paste, inviting supplemental briefing on statute of limitations.
- No damages were awarded; no injunction was issued against Sandoz or its current operations.
Financial Impact
No damages awarded or quantified in this ruling. The case remains pending with potential future exposure if Sandoz is found liable at trial.
Risk Factors
- If Sandoz is found liable at trial, potential treble damages and state penalties could be material, though no amount has been quantified.
- The case involves 36 defendants and dozens of drugs; a coordinated defense may still result in significant aggregate exposure.
- Adverse trial outcome could invite follow-on private lawsuits from direct purchasers and insurers.
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-4935d34191-SDZ |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | Court Ruling | — | awaiting T+20 | — | — |
Oct 7, 2026 20d ago | Court Ruling | — | awaiting T+20 | — | — |
Sep 30, 2026 27d ago | Court Ruling | — | awaiting T+20 | — | — |
Sep 30, 2026 27d ago | Court Ruling | — | awaiting T+20 | — | — |
Sep 11, 2026 6w ago | Court Ruling | — | awaiting T+20 | — | — |
Aug 12, 2026 10w ago | Court Ruling | — | awaiting T+20 | — | — |
Aug 6, 2026 11w ago | Court Ruling | — | awaiting T+20 | — | — |
Jul 22, 2026 13w ago | Court Ruling | — | awaiting T+20 | — | — |
Jul 8, 2026 15w ago | Court Ruling | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers